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Abstract
Background: In the last years the knowledges on Mediterranean Buffalo (MB) mastitis is remarkably improving,
nevertheless the attention has been never focused on vaccination as preventive strategy for the control of mastitis
in these ruminates. The aim of the current study was to assess clinical efficacy over time of two different preventive
vaccination protocols against S. aureus mastitis, in primiparous MB.Vaccinated (VG) and not-vaccinated (N-VG)
groups, of 30 MB each one, were selected from two different herds (herd A: VG1 and N-VG1; herd B: VG2 and N-
VG2) of the same farm. Herd A received a double vaccination (Startvac®, 45 and 10 days before calving, protocol A),
while in herd B an additional administration was performed (52 days after calving, protocol B). Bacteriological milk
culture and assessment of somatic cell count (SCC) were performed at 10, 30, 60 and 90 days in milk (DIM) from
composite milk samples. After 90 DIM, daily milk yields and SCC values were monthly detected until dry-off.
Results: The overall incidence of positive MB for S. aureus was 40.8% (49/120) in VG1 and 43.3% (52/120) in N-VG1
(Protocol A), while 45.8% (55/120) and 50.8% (61/120) in VG2 and N-VG2 (Protocol B). The latter was associated
with a significant decreased in prevalence (at 90 DIM) and incidence of mastitis (animals positive for S. aureus,
SCC > 200^103, with or without clinical signs) in the vaccinated MB, while no difference occurred in protocol A.
Moreover, herd B showed a significant reduction in prevalence of intramammary infection (animals positive for S.
aureus, SCC < 200^103, no clinical signs) in the vaccinated MB at 60 DIM while no differences were detected in herd
A, at any sampling time; N-VG2 had significantly higher overall SCC values than VG2 (4.97 ± 4.75 and 4.84 ± 4.60
Log10 cells/mL ± standard deviation, respectively), while no differences were recorded in herd A.
Conclusions: The current investigation explores for the first time the clinical efficacy of vaccinations against S.
aureus infections in MB, showing encouraging results regarding reduction in mastitis and somatic cell count; the
polyvalent mastitis vaccine may be considered an additional tool for in-herd S aureus infection and should be
associated to other control procedures to maximize its properties.
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Background
Mastitis represents one of the major causes of economic
loss in dairy Mediterranean buffaloes (MB) because
negatively influencing milk quality and yields of the ani-
mals affected [1, 2]. In MB mastitis is mainly caused by
several contagious (e.g. Staphylococcus aureus, Strepto-
coccus agalactiae), environmental (e.g. Streptococcus
uberis and Streptococcus dysgalactiae, Escherichia coli,
Enterobacteriaceae, and yeasts), and opportunistic (e.g.
coagulase-negative staphylococci) bacteria [3–5].
S. aureus is one of the most important pathogens,
causing clinical and subclinical mastitis in dairy MB and
cows all over the world [2, 6, 7]; Clinical outcomes and
high within-herd prevalence were recently described in
MB confirming its relevance as contagious microorgan-
ism [2]. This bacteria typically colonizes the injured skin;
damage of the teat end and faulty milking encourages
migration of bacteria into the udder causing intramam-
mary infections (IMI) and sometimes persisting for ex-
tended periods [4, 8, 9]. Some strains are particularly
resistant to antibiotics [4] and moderate results were re-
ported in an our previous study exploring the effects of
an antibiotic selective treatment [1]. As a consequence,
similarly to dairy cows additional strategies of herd
health management including treatment or culling of af-
fected animals, implementation of biosecurity measures
and hygienic milking practices, have been recommended
to prevent and control udder health problems related to
S. aureus in MB farms [2].
Although with different outcomes, great scientific at-
tention was recently given to mastitis control by means
of preventive vaccination protocols in cows [10–16]. A
commercial multivalent vaccine containing inactivated S.
aureus and E. coli has been available in European Union
for the last years and several investigations regarding its
usefulness were recently performed in cows with differ-
ent results [13, 14, 17]. In MB, the awareness for mastitis
are remarkably improving, although the attention has
been never focused before on vaccination as preventive
strategy for mastitis.
Considering the premises, the aims of the present
study was to evaluate the clinical efficacy of a polyvalent
commercial vaccine administered in dairy primiparous
MB evaluating as outcomes (1) the prevalence and inci-
dence of IMI and mastitis, (2) the effects on somatic cell
count and (3) milk yield.
Methods
Animals and Farm Management
All the animals chosen in the present study were reared
in the same breeding farm of approximately 700 dairy
buffaloes, free from mandatory reportable diseases and
located in Caserta area (Southern Italy). The eligible cri-
teria for the farm were represented by 3, monthly and
consecutive samplings of bulk tank milk positive for S.
aureus before the beginning of the study, analyzed by
means of PCR-based assay as described by Syring et al.
[18]. No strict criteria were instead applied for bulk milk
somatic cell count (SCC) or mastitis incidence. Differ-
ences observed about herd management practices were
recorded during the period of the investigation (two
consecutive years) to exclude possible influences on vac-
cination efficacy.
Farm was characterized by herringbone parlor and ani-
mals were milked twice a day. A mean of 247 ± 23-day
milk yield per head of 2200 kg while mean bulk tank
SCC values of 172 × 103 ± 49 × 103 and 179 × 103 ± 32 ×
103 cell/mL were recorded for the whole herd during the
first and the second year of investigation, respectively.
All MB selected were kept in a roofed common paddock
of ~ 1200 m2 (~30 m × 40 m) As often observed in MB’s
farms, before parturition and until 40–50 DIM, all the
primiparous MB were housed separated from the pluri-
parous. Milking was performed in the same milking par-
lor, although the primiparous animals were milked first.
After 50 DIM, primiparous were mixed with the pluri-
parous animals, including milking time. The barn was
characterized by a common bedded area (with dried ma-
nure solids), a loafing area and a feeding alley with solid
non-grooved concrete floor (cleaned twice a day). The
entire herd was fed a total mixed ratio including hay, sil-
age and a multi-vitamin integrator three times a day;
free access to the protected water trough was always
guaranteed.
Study design
Two herds (A and B) were enrolled in the current study.
Sixty primiparous for each herd were subdivided into
two groups of 30 MB: vaccinated and not-vaccinated
(herd A: VG1 and N-VG1; herd B: VG2 and N-VG2).
Animals were chosen from the same farm in two con-
secutive lactations (herd A: I year, December 2012 to
November 2013 - herd B: II year, December 2013 to No-
vember 2014). Every year the animals were chosen by
means convenience sampling from 80 primiparous in
good health having 4 functional quarters, teats free of
significant lesions, and with an estimated calving date to
allow vaccination at predicted times before calving. Sam-
ples size was calculated by using the formula proposed
by Thrusfield [19] considering the following values:
study population (pregnant primiparous MB in farm,
~14% of entire herd – approximately stable parameter in
both years considered), expected prevalence of positive
primiparous MB for S. aureus (55%) [1], confidence
interval 95% and desired absolute precision (5%).
All the animals were individually submitted to a
complete clinical examination with particular focus on
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the udder health status following the clinical procedure
described by Ciaramella [20].
For each herd the progressive vaccination was per-
formed on 50 MB were chosen by means of simple
randomization; out of the latter, the first 30 animals
reaching the entire vaccination protocol were enrolled as
VG. The other 30 not vaccinated subjects were selected
as N-VG.
On sampling day, local and systemic signs and changes
in milk appearance, such us overall appearance of de-
pression, udder swelling and pain, off-color and watery
appearance of milk, and presence of flakes, clots or pus,
were recorded. California Mastitis Test (CMT) was rou-
tinely performed from each composite milk sample, with
values ≥1 interpreted as positive [2] (data not shown).
Vaccine
Commercial polyvalent mastitis vaccine (STARTVAC®,
HIPRA Spain Co. Ltd, Girona) containing inactivated E.
coli J5 and inactivated S. aureus (CP8) strains SP 140,
expressing slime-associated antigenic complex (SAAC)
was used [21].
The farmer was previously informed about the pur-
poses and methods of the two clinical field-trials and the
study received the approval by the Ethical Animal Care
and Use Committee of University of Studies of Naples
“Federico II”. During the present investigation each herd
was submitted to a different vaccination protocol: the
first (protocol A - herd A) was based on two intramus-
cular vaccine injections located at the medium third of
the neck (2 mL each one) and performed at 45 and
10 days before the estimated date of calving on VG1; the
second one (protocol B - herd B), instead included an
additional administration on VG2 at 52 days in milk
(DIM).
Milk Samples
All milk samples were aseptically collected in sterile test
tubes immediately before regular evening milking, as de-
scribed by National Mastitis Council [22] for dairy cows.
At 10, 30, 60 and 90 DIM, a sample from each quarter
was collected; a composite milk sample was created by
mixing equal amounts of milk (50 mL) from all 4 quar-
ters into a sterile test tube (BD Vacutainer, Oxford, UK)
and used to perform bacteriological milk culture (BMC)
and determine the SCC; finally, milk yields were also re-
corded during the same samplings time using automatic
dedicated software (Afifarm, Afimilk, Kibbutz Afikim,
Israel). After 90 DIM, milk yield and SCC values were
evaluated at 150 and 240 DIM (close to dry off ). As de-
scribed by a previous study [1], a great variability to
achieve the supposed drying-off time (daily milk yield <
0.5 L/day) was detected in the enrolled animals (from
240 to 260 DIM), as consequence, the last sample
considered useful for the statistical and economic ana-
lysis was collected at 240 DIM.
Definition of Udder Health Status
Following the classification reported in previous studies
[1, 23], the animals enrolled were defined as negative for
S. aureus, affected by IMI or mastitis considering: pres-
ence/absence of clinical signs, SCC values, and micro-
biological status; briefly, MB producing milk with SCC
below the threshold of 200 × 103 cells/mL and associated
with BMC negative to S. aureus were considered and
hereafter referred to as “healthy udder”; animals with
analogous SCC values and positive BMC caused by S.
aureus have been instead considered affected by IMI;
moreover, buffaloes producing milk with SCC upon the
threshold of 200 × 103 and positive BMC for S. aureus
have been defined as affected by mastitis, with (clinical
mastitis - CM) or without clinical signs (subclinical mas-
titis - SCM) [1, 23]. All the MB affected by mastitis (CM
and/or SCM) due to S. aureus were considered in end-
point phase and excluded from the study.
Cytological and bacteriological investigations
Composite milk samples were placed in a cool box
(4 °C) and brought to the reference laboratory within
1 h (h) of collection, where they were submitted to
SCC analysis and BMC within 2 h of collection. SCC
was determined using an automatic analyzer, approved
for buffalo milk (Fossomatic 5000, Foss Electric, Hil-
lerod, Denmark) [24]. The BMC and bacteriological
identification were performed according to guidelines
of the National Mastitis Council [25]. Briefly, 10 μL
of each milk sample was streaked on one quarter of a
blood-agar plate (Merck KGaA, Darmstadt, Germany),
incubated at 37 °C for up to 48 h and examined two
time (at 24 and 48 h of incubation). Bacterial colonies
were tentatively identified on gross morphology; number
and types of colonies were also recorded. As described in
previous studies [2], when 3 or more dissimilar colony
types were isolated on the plate, the sample was consid-
ered contaminated. Gram staining and catalase testing
were performed to differentiate between streptococci and
staphylococci, and tube coagulase testing using rabbit
plasma to differentiate between coagulase-positive and
coagulase-negative staphylococci. A final identification of
microorganisms was performed using the colorimetric
automated identification system (Vitek 2 XL 120; bioMer-
ieux Inc., Hazelwood, MO), according to the manufac-
turer’s instructions. Enterobacteriaceae were grown on
MacConkey agar (Oxoid, Basingstoke, UK) and identified
using the same automated system. Isolates identified with
confidence levels greater than 0.90 were considered identi-
fied mastitis pathogens at species level; otherwise, they
were identified at genus level.). All the laboratory
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procedures were performed without previous informa-
tions about the results of the clinical examination of the
udder (physical and CMT).
Statistical analysis
Different animal health status, SCC, and milk yields
were analyzed by standard descriptive statistics and nor-
mality was assessed using histograms, normal probability
plots and Shapiro Wilk tests. Data were expressed as
absolute numbers, percentage, or mean ± SD. Log- trans-
formation was applied to variable not normally distrib-
uted. Untransformed and log-transformed continuous
variables (SCC and milk yields) were compared using
Student’s t-test. Significant differences between expected
and observed frequencies of categorical data (i.e. vaccine
efficacy: VG1 vs. N-VG1 and VG2 vs. N-VG2) were
assessed by means of contingency tables, using χ2-test.
Fisher’s exact test was performed in case of low expected
frequencies (<5). Probabilities <0.05 were considered sig-
nificant. Moreover, a mixed models were also used to in-
vestigate the direct effects of the vaccination intra- and
inter-protocols. The final model included fixed time ef-
fect, fixed group effect, fixed interaction time*group and
buffalo as random effect. For statistical analysis of the
outcomes a mixed linear models was used for continu-
ous data (SCC and milk yield); Bonferroni correction
was used to set P-value for multiple statistical test; the
threshold for statistical significance in our analysis was
P = 0.0052, the null hypothesis was rejected for P <0.01.
For categorical data (presence/absence of mastitis) a
mixed logistic models based only on fixed group effects
and buffalo-specific random effect was performed
because otherwise the function to be maximized was
not concave due to the small amount of observations.
Data inter-protocols (absolute values) were combined
in the model including time and group as fixed ef-
fects. Probabilities <0.05 were considered significant.
All the statistical data were analyzed using dedicated
software (STATA 12.0, StataCorp LP, Collage Station,
Texas, USA).
Results
Course of the study and prevalence of udder pathogens
No general or local adverse reactions to the use of the
vaccine was observed in all the buffaloes of both the
protocols after the administrations. The request number
of vaccinated animals was reached in 1.5 months in herd
A and in 2 months in herd B. Vaccinations were per-
formed 45.8 ± 4.1 and 11.1 ± 2.4 days pre-calving in
VG1, while 46.2 ± 4.6 and 10.3 ± 2.2 days-pre calving in
VG2; the additional vaccination expected for protocol B
was instead administered 52.2 ± 1.1 days post-calving.
During the two years of study, no differences about all
the aspects of herd management practices (e.g. feeding
and housing system, milking routine, dairy workers,
therapeutic protocols for mastitis, etc.) were detected.
Throughout the study, 480 composite milk samples
were collected and submitted to BMC. All udder patho-
gens isolated during the first 90 DIM in vaccinated and
not-vaccinated groups of the two herds and their relative
incidence are reported in Table 1. Briefly, the most com-
monly isolated pathogens in both the groups of the two
herds, were S. aureus followed by coagulase-negative
staphylococci. Positive-culture status for S. aureus was
detected in 30.2% (49/162) and 32.5% (52/160) of the
overall bacteriological results in VG1 and N-VG1, re-
spectively; it was instead recorded in 41.9% (55/131) and
50.4% (61/121) of the samples in VG2 and N-VG2, re-
spectively. E. coli was only detected in both groups of
herd B (VG2: 1 time, 0.8% and N-VG2: 2 times, 1.7%,
Table 1) and associated with not severe CM (mild milk
change, CMT ≥2).
The overall percentage of positive samples for other
udder pathogens, except for S. aureus and E. coli, was
29.6% (48/162) in VG1 and 30.6% (49/160) in N-VG1,
while it was 35.9% (47/131) and 23.9% (29/121) in VG2
and N-VG2, respectively.
Negative-culture status was observed in 40.1% (65/
162) and 36.9% (59/160) of the all bacteriological results
observed in VG1 and N-VG1, respectively; 21.4% (28/




The 40.8% (49/120) and 43.3% (52/120) of the samples
collected were positive for S. aureus in VG1 and N-VG1.
No bacteria were detected at 10 DIM (0/30) in VG1,
while their presence increased up to 16.7% (5/30), 60.0%
(18/30) and 89.2% (25/28) at 30, 60 and 90 DIM, re-
spectively; in N-VG1 the prevalence of positive-cultures
for S. aureus was instead of 3.3% (1/30), 33.3% (10/30),
53.6% (15/28) and 92.8% (26/28) at 10, 30, 60 and 90
DIM, respectively; no statistically significant difference
was found regarding this variable between VG1 and N-
VG1 at any sampling time.
Details regarding of the effects of S. aureus on udder
health are reported in Table 2. Briefly, two CM due to S.
aureus were recorded both in VG1 (6.6%, 2/30) and N-
VG1 (6.6%, 2/30), at 60 and 30 DIM, respectively.
During the investigation, no SCM due to S. aureus were
detected between 10 and 60 DIM in both groups, while
they were observed both in VG1 (14.3%, 4/28) and N-
VG1(10.7%,3/28) at 90 DIM. No statistically significant
difference between prevalence of mastitis in VG1 and N-
VG1 was observed. During the first 90 DIM, no statisti-
cally significant difference was recorded between the
incidence of mastitic animals in VG1 (20.0%, 6/30) and
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Table 1 Bacteriological results of all samples collected in both the herds of primiparous Mediterranean buffalo during the first
90 days in milk of investigation. Percentages represent the proportion calculate on the total number bacteriological results
Herd A Herd B
VG1 N-VG1 VG2 N-VG2
Pathogens No. Percent No. Percent No. Percent No. Percent
Staphylococcus aureus 49 30.2 52 32.5 55 41.9 61 50.4
Coagulase-negative staphylococci 32 19.9 32 19.3 41 31.3 16 13.1
Enterococcus faecalis 2 1.2 2 1.3 1 0.8 1 0.8
Aerococcus viridans 4 2.5 4 2.5 2 1.5 4 3.3
Streptococcus dysgalactiae 2 1.2 1 0.6 0 0 2 1.7
Streptococcus thoraltensis 2 1.2 2 1.3 0 0 1 0.8
Other gram-positive pathogens (not S. aureus) 2 1.2 5 3.1 3 2.3 2 1.7
Escherichia coli 0 0 0 0 1 0.8 2 1.7
Acinetobacter lwoffii 4 2.5 3 1.9 0 0 2 1.7
Bacillus spp. 0 0 0 0 0 0 1 0.8
Culture negative 65 40.1 59 36.9 28 21.4 29 24.0
Total 162 100 160 100 131 100 121 100
No = number; VG1 and N-VG1 = Vaccinate Group1 and Not-Vaccinated Group1, respectively; VG2 and N-VG2 = Vaccinate Group1 and Not-Vaccinated Group2,
respectively. Herd A: received two doses of vaccine pre-calving; Herd B: received two doses of vaccine pre-calving and one post-calving
Table 2 Udder health status in primiparous Mediterranean buffalos within the two study herds (A and B) in association with
Staphylococcus aureus detection in composite milk samples
Herd A
10 DIM 30 DIM 60 DIM 90 DIM
Udder health status Groups No. Percent No. Percent No. Percent No. Percent
CM VG1 0/30 0 0/30 0 2/30 6.6 0/28 0
N-VG1 0/30 0 2/30 6.6 0/28 0 0/28 0
SCM VG1 0/30 0 0/30 0 0/30 0 4/28 14.3
N-VG1 0/30 0 0/30 0 0/28 0 3/28 10.7
IMI VG1 0/30 0 5/30 16.7 16/30 53.3 22/28 78.6
N-VG1 1/30 3.3 8/30 26.6 15/28 53.6 23/28 82.1
Healthy VG1 30/30 100 25/30 83.3 12/30 40.0 2/28 7.1
N-VG1 29/30 96.7 20/30 66.7 13/28 46.4 2/28 7.1
Herd B
CM VG2 0/30 0 0/30 0 0/28 0 0/27 0
N-VG2 0/30 0 0/27 0 0/23 0 0/20 0
SCM VG2 0/30 0 2/30 6.6 1/28 3.6 3/27a 11.1
N-VG2 3/30 10.0 4/27 14.8 3/23 13.0 5/20b 25.0
IMI VG2 2/30 6.6 12/30 40.0 14/28a 50.0 21/27 77.8
N-VG2 1/30 3.3 15/27 55.5 20/23b 86.9 13/20 65.0
Healthy VG2 28/30 93.3 16/30 53.3 13/28c 19.1 3/27 11.1
N-VG2 26/30 86.7 8/27 29.3 0/23d 0 2/20 10.0
VG1 and N-VG1 = Vaccinate Group1 and Not-Vaccinated Group1, respectively; VG2 and N-VG2 = Vaccinate Group1 and Not-Vaccinated Group2, respectively. CM =
Clinical Mastitis; SCM = Subclinical Mastitis; IMI = Intramammary infection; DIM = Days in Milk. Herd A: received two doses of vaccine pre-calving; Herd B: received
two doses of vaccine pre-calving and one post-calving. Animals affected by mastitis (SCM or CM) were considered in end- point. a,bP <0.01, c,dP <0.001
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N-VG2 (16.7%, 5/30). Regarding the prevalence of MB
affected by IMI or with healthy udder, data are reported
in detail in Table 2; no statistically significant difference
between prevalence of IMI or healthy udder was found
in VG1 and N-VG1 at any sampling time.
Details regarding of the effects on SCC and milk yield
are reported in Table 3. Briefly, during the protocol A,
the overall averages of Log10 SSC values observed during
the whole lactation were 4.93 ± 4.71 Log10 cells/mL in
VG1 and 4.95 ± 4.78 Log10 cells/mL in N-VG1 (IMI +
healthy udder MB); no statistically significant difference
was found between the two values as well as between
the daily mean values of SCC recorded at all sampling
times in VG1 and N-VG1. Regarding the milk yields, the
overall mean values observed in the same animals (IMI
+ healthy udder MB) during the entire investigation were
9.70 ± 2.07 L/day in VG1 and 9.35 ± 1.57 L/day in N-
VG1; no statistically significant difference was recorded
for this parameter at any sampling time.
Protocol B
The 45.8% (55/120) and 50.8% (61/120) of the samples
cultured were positive for S. aureus in VG2 and N-VG2,
respectively. The prevalence of positive-cultures for S.
aureus in VG2 was 6.6% (2/30) at 10 DIM and increased
up to 46.7% (14/30), 53.6% (15/28) and 88.9% (24/27) at
30, 60 and 90 DIM, respectively; in N-VG2 it was in-
stead of 13.3% (4/30), 70.4% (19/27), 100% (23/23) and
90.0% (18/20) at 10, 30, 60 and 90 DIM, respectively; a
statistically significant difference was found between
VG2 and N-VG2 at 60 DIM (P < 0.001).
Details regarding of the effects of S. aureus on udder
health are reported in detail in Table 2. No CM due to S.
aureus were recorded during the entire protocol in both
groups (VG2 and N-VG2). SCM were detected at 30,
(6.6%, 2/30), 60 (3.6%,1/28) and 90 DIM (11.1%,3/27) in
VG2, while in N-VG2, they were detected at each sam-
pling time with a prevalence ranged between 10% and
25%. A statistically significant difference was found at 90
DIM (P <0.01). During the first 90 DIM, a statistically
significant difference between the incidence of animals
affected by mastitis in was also recorded (VG2: 20.0% -
6/30 and N-VG2: 50.0% - 15/30, P <0.05). According to
the mixed logistic model the VG2 animals had less 23%
of probability to develop mastitis compared to N-VG2
(P <0.001). Regarding the prevalence of MB affected by
IMI and with healthy udder a statistically significant dif-
ference between prevalence of MB affected by IMI in
VG2 and N-VG2 was found at 60 DIM (P <0.01), while
between healthy udder at 60 DIM (P <0.001).
Details regarding of the effects on SCC and milk yield
are reported in Table 3. Briefly, during the protocol B,
the overall average of Log10 SSC values observed during
the whole lactation were 4.84 ± 4.60 Log10 cells/mL in
VG2 and 4.97 ± 4.75 Log10 cells/mL in N-VG2 (IMI +
healthy udder MB); a statistically significant difference
was found between the two values (P <0.05). A statisti-
cally significant difference was also recorded between
daily mean values of SCC in VG2 and N-VG2 at 10
(P <0.05), 30 (P <0.05), 150 (P <0.05) and 240 DIM
(P <0.01). Regarding the milk yields, the overall mean
values observed in the same animals during the entire
investigation were 10.37 ± 2.18 L/d in VG2 and 10.03 ±
2.28 L/d in N-VG2; no statistically significant difference
was recorded at any sampling time between the two
groups. The mixed linear model confirmed a significant
Table 3 Daily means somatic cell count values (Log10 cells/mL ± SD) and milk yields (Litres ± SD) detected in VGs and N-VGs in both
the herds of primiparous Mediterranean buffalo during 240 days in milk of study
DIM
Item 10 30 60 90 150 240
Herd A -Log10 SCC
VG1 4.84 (±4.51) 4.73 (±4.62) 4.82 (±4.54) 5.10 (±4.75) 5.02 (±4.90) 5.08 (±4.95)
N-VG1 4.88 (±4.65) 4.80 (±4.68) 4.87 (±4.77) 5.05 (±4.92) 4.98 (±4.89) 5.09 (±4.78)
Herd B -Log10 SCC
VG2 4.86 (±4.60)a 4.67 (±4.45)a 4.86 (±4.71) 4.97 (±4.66) 4.84 (±4.51)a 4.85 (±4.67)c
N-VG2 4.99 (±4.74)b 4.94 (±5.01)b 4.87 (±4.69) 4.87 (±4.73) 4.98 (±4.67)b 5.15 (±4.64)d
Herd A –Milk Yields
VG1 7.85 (±0.85) 13.10 (±2.56) 13.04 (±2.77) 12.19 (±2.59) 8.63 (±2.13) 3.37 (±1.51)
N-VG1 7.31 (±2.36) 12.89 (±2.20) 13.20 (±2.21) 11.63 (±1.48) 8.01 (±0.56) 3.05 (±0.59)
Herd B –Milk Yields
VG2 8.50 (±2.04) 13.39 (±2.27) 13.66 (±2.15) 13.87 (±2.89) 8.84 (±1.94) 3.98 (±1.77)
N-VG2 7.7 (±2.12) 13.08 (±2.53) 13.10 (±2.83) 12.41 (±2.34) 9.57 (±4.89) 4.34 (±1.57)
VG1 and N-VG1 = Vaccinate Group1 and Not-Vaccinated Group1, respectively; VG2 and N-VG2 = Vaccinate Group1 and Not-Vaccinated Group2, respectively; DIM =
days in milk; a,bP <0.05,c,dP <0.01. Herd A: received two doses of vaccine pre-calving; Herd B: received two doses of vaccine pre-calving and one post-calving
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difference between mean SCC of VG2 and N-VG2 at
150 (−66611.1, P <0.001) and 240 (−76444.4, P <0.01)
DIM. No difference where instead detected regarding
milk yields.
Finally, combining the two field trial, the mean differ-
ence of SCC between VG2 and N-VG2 was significantly
higher than the analogous difference between VG1 and
N-VG1 (−19778.06, P <0.05). No significant differences
were instead observed regarding the milk yields.
Discussion
For the purposes of the analysis outlined in this paper,
the efficacy of two different regimens of vaccination,
based on the use of a multivalent commercial inactivated
bovine vaccine against S. aureus mastitis, was compared
for the first time in MB during the lactation. Estimation
of vaccine effects against contagious infections and mas-
titis under field conditions is an interesting challenge in
species like MB where the knowledges regarding the
preventions of mastitis are truly rare.
The high prevalence of mastitis due to S. aureus
mono-infection reported in these ruminants [1], has
been confirmed also in the present investigation. In this
context, the influence of the dilution effects of S. aureus
due to composite milk samples use has been not consid-
ered substantial, as described for cows [26]. Instead, the
lack of quarter milk samples could represent a restric-
tion of the present study because of lower sensibility of
IMI detection and loss of useful information on quarter
level (e.g. new infection rate, bacteriological cure rate,
duration of the infections).
During the survey, only primiparous MB were enrolled
because our previous studies showed a high-frequency
isolation of S. aureus in first lactating animals between
30 and 90 DIM [1, 2, 5] and also to exclude the potential
negative influence of a poor management of dry period.
The complete lack of previous knowledge concerning
preventive vaccination against mastitis in MB, lead the
authors in a careful and methodical approach for the
evaluation of the outcomes of a vaccine produced in ori-
gin for dairy cows; for this reason, two different regi-
mens were carried out according to the manufacturer's
instructions verifying the tolerance of the animals to the
product, the effects on udder health, the milk quality
and yields.
As described by Schukken et al. [13] for cows, also for
MB the analysis of the data regarding the efficacy esti-
mates was focused on the animals that received the full
vaccination protocols; despite the ambition to vaccinate
the animals according to the vaccination schemes planned,
some difficulties were detected to achieve the necessary
number of vaccine doses planned because of a continuous
and precise scheduling required, inaccurate estimation of
duration of pregnancy, early loss of pregnancy, abortions
or MB calving pretermly. Given that incomplete vaccin-
ation due to the reasons described could be a common
finding also in many MB herds, it is possible that our
estimates of vaccine efficacy could be overestimated
compared with the efficacy observed under true field
conditions.
The importance of S. aureus as a contagious pathogen
has been widely recognized both in dairy buffaloes and
cows because cause of mastitis and relevant economic
losses due to its negative influence on milk quality and
yields [2, 6]. A previous study investigating clinical rele-
vance and genotype of S. aureus in MB, elucidated that
(1) genotype B was the only one detected, (2) it was as-
sociated to high within-herd prevalence (up to 55%) and
incidence (up to 20.4%, during the whole lactation
period), (3) it was responsible of contagious mastitis [2].
As well established also for cows, some strains of S. aur-
eus (e.g. genotype B) are related to high contagiousness,
causing herd problems with a within-herd prevalence of
up to 87% [27]. A high prevalence and incidence of posi-
tive MB for S. aureus was also detected in both proto-
cols and groups of the current investigation confirming
the high-frequency isolation of this pathogen. Moreover,
considering the overall cultured milk samples, S. aureus
was also the most frequently isolated bacterium in both
the herds and groups followed by coagulase-negative
staphylococci. The result confirms a similar findings re-
cently observed both in MB [2] and cows herds [28]
where the percentage of isolation of coagulase-negative
staphylococci and Streptococci were indeed considerably
lower in herds positive for S. aureus showing high conta-
giousness and pathogenicity.
A significant difference in the overall rate of mastitis,
comparing unvaccinated and vaccinated MB, was ob-
served only in herd B. The administrations of 3 doses of
vaccine, may significantly reduce the incidence of mas-
titis within the herd; the difference seems to be related
to the lower prevalence of SCM detected at any sam-
pling time in the VG2 than N-VG2 and achieving a
significant peak at 90 DIM. Therefore, the novel contribu-
tion of the current study has been to show encouraging
results regarding the efficacy of the inactivate vaccine on
MB, in contrast with some previous similar studies on
staphylococcal vaccination in dairy cows described rela-
tively low vaccine efficacy or no vaccine efficacy at all [15,
17]. However, it is necessary to underline that another of
the restrictions of the present investigation may be repre-
sented by the chosen study design: indeed only the direct
vaccine effects, without attempt to estimate the overall
population estimates, were described; as a consequence, it
possible that our outcomes may be overestimated if com-
pared with the truly observed vaccine efficacy under over-
all population conditions. Furthermore, the presence of
CM in herd A (VG and CG) suggests that the protocol
Guccione et al. BMC Veterinary Research  (2017) 13:29 Page 7 of 9
based on 2 vaccine administrations had not effect to pre-
vent the appearance of clinical signs; on the contrary, in
herd B, no difference has been found in both the groups
considered overtime and therefore it has been not possible
to evaluate this effect. The finding merits further scientific
attention, because of the small number of animals enrolled
and the lack of previous studies performed on MB useful
to compare the results observed.
Regarding IMI due to S. aureus, a high prevalence
of MB infected was recorded in both the protocols al-
though lower rate of infection was observed in VGs
than N-VGs in almost all the samplings. During the
investigation a higher prevalence of infections was al-
ways observed between 60 and 90 DIM in both the
protocols and groups; these effects may have been
caused by mixing primiparous with pluriparous ani-
mals in the herds, as initiated by the farmer between
40 and 50 DIM. It is interesting to highlight how the
administration of the third dose seems to decrease
significantly the prevalence of IMI between VG2 and
N-VG2 at 60 DIM, conversely to the use of two
doses. Moreover, the moderate reduction of IMI ob-
served in this sampling time, may have consequently
reduced the mastitis prevalence observed in the suc-
cessive control time; the finding described may be
also supported by the significant higher percentages
of healthy udder MB recorded in VG2 than N-VG2
at 60 DIM. The results observed seem less encour-
aging than those recently described for cows where
vaccination resulted in moderate reduction in inci-
dence of new infections and more pronounced reduc-
tion in duration although in presence of an efficacy
for transmission still relatively low [13]. As reported
by several studies in cows [27–29], also in our inves-
tigation the vaccine effects on IMI may be influenced
by farm-specific characteristics, such as strain types
and farm management practices, and not be only as-
cribed to the vaccine’s properties. Excellent preventive
herd management strategies may contribute to signifi-
cantly reduce the overall herd exposure to S. aureus
both in MB and cows [2, 13, 30], resulting in an im-
portant contribution to indirect vaccine efficacy.
Regarding the effects of vaccination on milk yield and
quality, no significant differences were observed between
the overall mean milk yields and daily mean production
between the two groups of both protocols, while a
significant difference between the two regimens was
observed regarding SCC. As reported in Table 3, the
protocol A was not able to positively influence SCC
values in VG1 compared with N-VG1, differently from
the protocol B, in which the additional vaccine’s dose
may have produced an additional immunization of VG
able to reduce S. aureus multiplication in the mammary
gland as reported also for cows [15]; therefore, the
additional administration seems to significantly decrease
SCC values in the successive days in milk and take part
in the significant difference observed on overall SCC
mean values. Moreover, the decrease of S. aureus’ nega-
tive effects seems to be also confirmed by the lower
prevalence of mastitis recorded from 30 to 90 DIM in
VG2 than N-VG2.
Conclusions
The current study represents the first investigation
evaluating direct effects of vaccination against S. aureus
in dairy Mediterranean Buffalo. Even though this study
included only a small number of animals, the use of
inactivated vaccine by means of the protocol B (based
on label use) shows encouraging results because associ-
ated with significant lower prevalence and incidence of
mastitis as well as lower SCC values, than the protocol
A (based on two doses). Nevertheless, the lack of large-
scale effects against IMI highlights that vaccination in
MB, as in cow, may be considered only an additional
tool in the control of S. aureus infections on farms and
that its use should be always associated with excellent
farm management practices to successfully improve the
infections control within the herd. The assessment of its
effects on the entire dairy MB herd under field condi-
tions, as well as the in-depth analysis of the infectious
dynamics, warrant further scientific attention with the
goal to fully understand the potentialities of this inacti-
vated vaccine in dairy buffalo management.
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